| Hai Ly, CRNA | |
|
101 The City Dr S, Orange, CA 92868-3201 | |
| (714) 456-7890 | |
| Not Available |
| Full Name | Hai Ly |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 101 The City Dr S, Orange, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194365775 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | NA95001245 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Irvine Medical Center | Orange, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Medical Doctors | 2961305651 | 105 |
| Regents Of The University Of | 8729983473 | 159 |
News Archive
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The Institute of Tropical Medicine in Antwerp (ITM), with support from the Agency for Innovation by Science and Technology (IWT), launches the Be-PrEP-ared project on Thursday 10 September.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture
› Verified 2 days ago
| Entity Name | Regents Of The University Of |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487602546 PECOS PAC ID: 8729983473 Enrollment ID: O20031204001085 |
News Archive
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The Institute of Tropical Medicine in Antwerp (ITM), with support from the Agency for Innovation by Science and Technology (IWT), launches the Be-PrEP-ared project on Thursday 10 September.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture
› Verified 2 days ago
| Entity Name | United Medical Doctors |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770559981 PECOS PAC ID: 2961305651 Enrollment ID: O20040129001069 |
News Archive
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The Institute of Tropical Medicine in Antwerp (ITM), with support from the Agency for Innovation by Science and Technology (IWT), launches the Be-PrEP-ared project on Thursday 10 September.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hai Ly, CRNA 200 S Manchester Ave Ste 300, Orange, CA 92868-3219 Ph: (714) 456-2986 | Hai Ly, CRNA 101 The City Dr S, Orange, CA 92868-3201 Ph: (714) 456-7890 |
News Archive
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.
The Institute of Tropical Medicine in Antwerp (ITM), with support from the Agency for Innovation by Science and Technology (IWT), launches the Be-PrEP-ared project on Thursday 10 September.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture
› Verified 2 days ago
Miranda G Ideal, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Michelle Smith Aquino, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Amy Louise Owens, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7890 | |
Kaitlin Dempsey, DNP, CRNA, RN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7890 | |
Amy D Kosanke, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-5261 | |
Sara Hollmann Learned, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7890 |